You are invited to attend a live Web conference, using Premiere Conferencing's VisionCast ® powered by Microsoft Office LiveMeeting Conference Center 2005.
Please test your browser for compatibility at the following URL prior to the event date: http://www.livemeeting.com/cc/vcsales/join?id=GPMN4J&role=attend&pw=XHGS8K
If you cannot access the browser check by using that link, please copy this link: http://www.livemeeting.com/cc/vcsales/join into your browsers address bar and enter the following information in the fields provided:
-- Enter your name in the "Your Name" field. -- Enter GPMN4J in the "Meeting ID" field. -- Enter XHGS8K in the "Password" field.
Follow The Link Below To Join The Meeting: When: Wednesday, Apr 10, 2007 4:30 PM (EDT) Scheduled to Occur: Once Duration: 1:00
https://www.livemeeting.com/cc/vcc/join?id=w8343700&role=attend&pw=A834370
Subject: VioQuest Pharmaceuticals Investor Web Conference Meeting URL: https://www.livemeeting.com/cc/vcc/join Meeting ID: w8343700 Meeting Key: A834370 Role: Attendee Audio Conferencing (Toll-free): 1-800/946-0705 Confirmation Code: 8343700 **Dial *0 for Technical Assistance** ** Remember: Please close your browser window at the end of the meeting to disconnect from the conferencing server**
About VioQuest Pharmaceuticals VioQuest Pharmaceuticals, Inc. http://www.vioquestpharm.com focuses on acquiring, developing, and commercializing targeted late preclinical and early clinical stage therapies with unique mechanisms of action for oncology, viral and autoimmune disorders. VioQuest has two targeted therapeutics in Phase I/IIa clinic trials: VQD-002 which inhibits phosphorylation of Akt that is seen at abnormally high levels in breast, ovarian, colorectal, pancreatic, and hematologic tumors; and Lenocta(TM), an inhibitor of specific protein tyrosine phosphatases, which has shown compelling preclinical activity in both renal and melanoma cancers. In addition, VioQuest and the U.S. Army are planning to submit an NDA to the FDA in 2007 for Lenocta(TM) for the treatment of leishmaniasis. VioQuest's subsidiary Chiral Quest, Inc., a pioneer in asymmetric chemocatalysis and custom synthesis, offers its proprietary technology products to well-known pharmaceutical and fine chemical companies worldwide to improve their production efficiencies and, in some instances, to increase the overall safety and efficacy of the underlying drug. VioQuest is seeking strategic alternatives for Chiral Quest, which may include its sale.
Forward-Looking Statements This press release contains forward-looking statements that involve risks and uncertainties that could cause VioQuest's actual results and experiences to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as anticipates, expects, plans, believes, intends, and similar words or phrases. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties, which could cause actual outcomes and results to differ materially from these statements. Among other things, there can be no assurances that the FDA will approve VioQuest's planned NDA submission relating to Lenocta(TM) for the treatment of leishmaniasis, and even if approved, there is no assurance that VioQuest will be able to successfully commercialize Lenocta(TM) for the treatment of leishmaniasis or any other indication, or that VioQuest will receive any proceeds in connection with a sale or other disposition of its Chiral Quest division. Other risks and uncertainties include the possibility that the results of clinical trials will not support VioQuest's claims, the possibility that VioQuest's development efforts relating to its product candidates, including Lenocta(TM) and VQD-002, will not be successful, the inability to obtain regulatory approval of VioQuest's product candidates, VioQuest's reliance on third-party researchers to develop its product candidates, its lack of experience in developing and commercializing pharmaceutical products, and the possibility that its licenses to develop and commercialize its product candidates may be terminated. Additional risks are described in VioQuest's Annual Report on Form 10-KSB for the year ended December 31, 2006. VioQuest assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
Contact information: Daniel Greenleaf President and CEO 908-766-4400 ext. 115 dan.greenleaf@vioquestpharm.com
Diane Perry VP, Investor Relations 917-834-7526 diane.perry@vioquestpharm.com
Brian Lenz Chief Financial Officer 908-766-4400 ext. 117 brian.lenz@vioquestpharm.com
Source: VioQuest Pharmaceuticals
